Decision Resources, Inc., April 2007, Pages: 17
’s Taxus stent and Cordis/Johnson & Johnson’s Cypher stent. What competitive opportunities does the potential for late stent thrombosis offer to manufacturers of other drug-elutingstents? How do current
Infiniti Research Limited, April 2012, Pages: 36
Drug-elutingStent Market in Europe 2011-2015 TechNavio’s analysts forecast the Drug-elutingStent market in Europe to grow at a CAGR of 4.3 percent over the period 2011–2015. One of the key factors
iData Research, Oct 2009, Pages: 102
European Markets for DrugEluting and Bare Metal Stents 2009 (15 Countries) The European market, as defined in this report, encompasses Germany, France, the United Kingdom (U.K.), Italy, Spain
Infiniti Research Limited, Feb 2012, Pages: 33
Drug-elutingStent Market in Japan 2011-2015 TechNavio’s analysts forecast the DES market in Japan to grow at a CAGR of 10.2 over the period 2011–2015. One of the key factors contributing
Frost & Sullivan, Dec 2010, Pages: 80
of this research. “The introduction of peripheral vascular drugelutingstents for the treatment of peripheral arterial disease (PAD) has opened up the market for other participants with novel combinations.”
Developments in imaging
GlobalData, May 2009, Pages: 43
Europe Coronary Stents Market: Revival of DrugElutingStents to Drive Growth Europe Coronary Stents Market: Revival of DrugElutingStents to Drive Growth
Summary
Our “Europe Coronary Stents
iData Research, May 2009, Pages: 65
U.S. Market for Drug-Eluting & Bare Metal Stents 2009 In 2008, the U.S. market for drugelutingstents was valued at $1.95 billion, representing an increase of 1.6% over 2007. Overall average selling
GlobalData, May 2009, Pages: 46
US Coronary Stents Market: Revival of DrugElutingStents to Drive Growth US Coronary Stents Market: Revival of DrugElutingStents to Drive Growth
Summary
Our “US Coronary Stents
Business Insights, Nov 2006, Pages: 137
of accessible indications for transdermal delivery.
- Drugelutingstents are typically 3 to 4 fold more expensive than bare metal stents and have elicited safety concerns, however next generation drug-eluting
